Search

Your search keyword '"Higgs, Richard E."' showing total 204 results

Search Constraints

Start Over You searched for: Author "Higgs, Richard E." Remove constraint Author: "Higgs, Richard E."
204 results on '"Higgs, Richard E."'

Search Results

2. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

Catalog

Books, media, physical & digital resources

3. Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab

6. Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients

10. Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab

11. The anti–SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination

12. The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination

13. Additional file 1 of Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab

15. Evaluation of the Relative Performance of Drug-Induced Skeletal Muscle Injury Biomarkers in Rats

17. The effect of anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, on endogenous immune response to COVID-19 vaccination

18. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together

20. A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load

21. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

23. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19

24. Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate‐to‐severe disease

25. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

26. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

27. From Ghrelin to Ghrelin's O-Acyl Transferase

29. Use of direct-infusion electrospray mass spectrometry to guide empirical development of improved conditions for expression of secondary metabolities from actinomycetes

30. Rapid method to estimate the presence of secondary metabolites in microbial extracts

31. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection

32. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways

33. Tu1853 SUSTAINED REDUCTION OF IL-23 RELATED CYTOKINES IL-17A AND IL-22 IN A PHASE 2 STUDY OF MIRIKIZUMAB IN THE TREATMENT OF PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS THROUGH WEEK 52

34. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients

35. O4 Baricitinib-induced changes in STAT-associated gene expression in systemic lupus erythematosus

36. A method for quantitatively differentiating crude natural extracts using high-performance liquid chromatography-electrospray mass spectrometry

39. THU0212 BARICITINIB-ASSOCIATED CHANGES IN GLOBAL GENE EXPRESSION DURING A 24-WEEK PHASE 2 CLINICAL SLE TRIAL DESCRIBE A MECHANISM OF ACTION THROUGH INHIBITION OF JAK/STAT AND IFN RESPONSIVE GENE EXPRESSION

40. Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk

41. Tu1712 – Reduction in Inflammatory Biomarkers in a Phase 2 Study of Mirikizumab in the Treatment of Patients with Moderatelyto-Severely Active Ulcerative Colitis

42. 185 Baricitinib-associated changes in type I interferon gene signature during a 24-week phase 2 clinical SLE trial

43. Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice

46. Abstract 29: Concordance of somatic mutations found in primary tumors and plasma circulating-free DNA from early and late-stage colorectal cancer patients

47. Evaluation of the Relative Performance of Drug-Induced Skeletal Muscle Injury Biomarkers in Rats

49. Identification of Druggable Cancer Driver Genes Amplified across TCGA Datasets